|
2010/06/24
Akiyama S1, Abe M1, Tomoda T2, Okamoto M3,4, Abe H1
1Kudan Clinic, Tokyo, Japan.,
2Seren Clinic, Tokyo, Japan.,
3Tella. Inc, Tokyo, Japan.,
4Res. Inst. of Pharmaceutical Sciences, Musashino Univ., Tokyo, Japan.
Abstract
Background: We have previously reported that vaccination with dendritic cells (DCs) loaded with WT-1 and/or MUC-1
can elicit immunological and anti-tumor responses. We describe here the preliminary results from retrospective analysis in
gastroenterological cancer patients received DC vaccination.
Methods: Sixty eight patients with advanced, inoperable gastroenterological cancer refractory to standard treatment were
entered the study. Immature DCs were generated from CD14+ monocytes from leukapheresis by 6-day cultivation with
GM-CSF and IL-4. DCs were matured by OK-432, a streptococcal agent, and were pulsed with WT-1 and/or MUC-1.
Each patient received 1 x 107 peptide-pulsed DCs 5 to 8 times at 2 week intervals. Induction of Tumor-specific cytotoxic T
lymphocyte (CTL) response was stimulated by DTH reaction more than 6mm.
Results:
Of the 68 patients enrolled all patients were evaluable, 18 with esophagus and gastric carcinoma, 32 with colorectal carcinoma
and 18 with pancreas carcinoma. Vaccination was well tolerated with toxicity limited to mild events (erythema in the site of injection
developed in the majority of patients). Clinical Response (RECIST): 43 patients showed evidence of 63.2% clinical benefit
(3 CR, 19 PR and 21 SD). Response rate was 32.4%.
Conclusions:
DC-based vaccination loaded with WT-1 and MUC-1 is safe and can elicit tumor regression. Substantial clinical benefit warrants
further development of DC vaccination.
• 2010, 제3회 세계암 학회
June 24, 2010 Singapore
|
